Pulmonx Plunges 12.96% Despite Q4 Revenue Beat

On March 28, 2025, Pulmonx's stock price dropped by 12.96% in pre-market trading.

Pulmonx has received a consensus rating of Moderate Buy from analysts. The company's average rating score is 2.78, based on 7 buy ratings and 2 hold ratings, indicating a generally positive outlook from the investment community.

Despite the recent drop in stock price, Pulmonx's average twelve-month target price among brokerages is $13.36, suggesting that analysts expect the stock to recover and potentially rise in the coming months.

Pulmonx reported a Q4 loss but exceeded revenue estimates, which could be a factor in the recent stock price movement. The company's financial performance and future outlook will be closely watched by investors.